
{{Act of Congress
| congress       = 113
| session        = 1
| pl             = 1
| title          = 
| override_previous = 
| statvolume     = 
| statpage       = 
| year           = 2013
| month          = 02
| day            = 08
| bill           = 594
| billtype       = hr
| notes          = 
| resolution     = 
| purpose        = To reauthorize and extend the Paul D. Wellstone Muscular Dystrophy Community Assistance, Research, and Education Amendments of 2008.
}}

{{Center|113th CONGRESS}}


{{Center|1st Session}}


{{Center|H. R. 594}}


{{Center|IN THE HOUSE OF REPRESENTATIVES}}


{{Center|February 8, 2013}}


{{Center|
[[Michael C. Burgess|Mr. Burgess]] (for
			 himself and 
[[Eliot Engel|Mr. Engel]]) introduced the
			 following bill; which was referred to the [[United States House Committee on Energy and Commerce|Committee on Energy and
			 Commerce]]}}



{{Center|A BILL}}

To reauthorize and extend the Paul D. Wellstone Muscular
		  Dystrophy Community Assistance, Research, and Education Amendments of
		  2008.


{{section|H13E31C7C9572417482BA0B0F2049223B|1. Short title}}
This Act may be cited as the
			 
          Paul D. Wellstone Muscular Dystrophy
			 Community Assistance, Research and Education Amendments of
			 2013

        
.

{{section|H130E50A948EB4DF7A8041BE3ECAFFEEF|2. Initiative through the Director of the National Institutes of Health}}
Section 404E of the Public Health Service
			 Act
 (42 U.S.C. 283g
)
 is amended—
(1)
in subsection
			 (a)(1)
—
(A)
by striking
			 Muscoskeletal
 and inserting Musculoskeletal
;
			 and

(B)
by inserting
			 Becker, myotonic, facioscapulohumeral muscular dystrophy (referred to in
			 this section as FSHD
), Congenital muscular dystrophy,
			 Limb-girdle muscular dystrophy,
 after Duchenne,
;


(2)
in subsection
			 (b)
—
(A)
in paragraph (2)
,
			 by inserting cardiac and pulmonary function,
 after
			 imaging, genetics,
; and

(B)
in paragraph (3)
,
			 by inserting and sharing of data
 after regular
			 communication
;


(3)
in subsection
			 (d)
—
(A)
in paragraph
			 (2)
—
(i)
in
			 the matter preceding subparagraph (A)
, by striking 15
 and
			 inserting 18
; and

(ii)
in
			 subparagraph (A)
, by striking children with muscular dystrophy, such as
			 the [[United States Department of Education|Department of Education]]
 and inserting children and adults
			 with muscular dystrophy, such as the [[United States Department of Education|Department of Education]], the [[Social Security Administration|Social
			 Security Administration]], the [[Department of Health and Human Services|United States Administration for Community
			 Living]]
; and


(B)
in paragraph
			 (4)(B)
, by inserting , and shall meet no less than two times per
			 calendar year
 before the period;


(4)
in subsection
			 (e)
—
(A)
in paragraph
			 (1)
—
(i)
in the matter preceding subparagraph (A)
,
			 by striking through the national research institutes
 and
			 inserting through the agencies represented on the Coordinating Committee
			 pursuant to subsection (d)(2)(A)

; and

(ii)
in
			 subparagraph (A)
, by striking and rehabilitative issues, including
			 studies of the impact of such diseases in rural and underserved
			 communities
 and inserting public resources, and rehabilitative
			 issues, including studies of the impact of such diseases in rural and
			 underserved communities, health economic studies to demonstrate the
			 cost-effectiveness of providing independent living resources and support to
			 patients with various forms of muscular dystrophy, and studies to determine
			 optimal clinical care interventions for adults with various forms of muscular
			 dystrophy
; and


(B)
in paragraph (2)
,
			 by adding at the end the following:
(F)
The development of
				clinical interventions to improve the health of adults with various forms of
				muscular dystrophy.

;
				and



(5)
in subsection (g)
,
			 by striking for the various forms of muscular dystrophy by prioritizing
			 the achievement of the goals related to this topic in the plan under subsection
			 (e)(1)

 and inserting and shall, not later than 6 months after
			 the date of enactment of the Paul D.
			 Wellstone Muscular Dystrophy Community Assistance, Research and Education
			 Amendments of 2013
, in coordination with appropriate Federal
			 agencies, including relevant offices within the [[Food and Drug Administration|Food and Drug Administration]]
			 and supported by the [[National Institutes of Health|National Institutes of Health]] and [[United States Department of Defense|Department of Defense]],
			 develop a plan to expedite the evaluation and approval of emerging therapies
			 and personalized medicines that have the potential to decrease fatal disease
			 progression across the various forms of muscular dystrophy
.


{{section|H969FA034327C49A198B02EE9A67CC116|3. Surveillance and research regarding muscular dystrophy}}
Section 317Q of the Public Health Service
			 Act
 (42 U.S.C. 247b–18
)
 is amended—
(1)
in the second
			 sentence of subsection (b)
, by inserting before the period the following:
			 and ensure that the program captures data from different racial and
			 ethnic populations, and that such data are made publicly available to
			 investigators conducting public or private research on muscular
			 dystrophy
; and

(2)
in subsection (c)
,
			 by adding at the end the following: The [[Department of Health and Human Services|Secretary]] shall also foster
			 ongoing engagement and collaboration between the surveillance program and
			 centers of excellence.
.


{{section|HE20E624237D14F3D871C90793365F9AA|4. Information and education}}
Section 5(c) of the
			 Muscular Dystrophy Community Assistance, Research and Education Amendments of
			 2001
 (42 U.S.C. 247b–19(c)
)
 is amended by adding at the end the
			 following:
(4)
Update and widely disseminate existing
				Duchenne-Becker muscular dystrophy care considerations for pediatric patients,
				develop and widely disseminate Duchenne-Becker muscular dystrophy care
				considerations for adult patients, and develop and widely disseminate acute
				care considerations for all muscular dystrophy populations. The care
				considerations should build upon existing efforts currently underway for
				congenital muscular dystrophy, fascioscapulohumeral muscular dystrophy,
				limb-girdle muscular dystrophy, and myotonic muscular dystrophy, and
				incorporate strategies specifically responding to the findings of the national
				transitions survey of minority, young adult and adult communities of muscular
				dystrophy
				patients.

.



